![](https://endpts.com/wp-content/uploads/2023/03/Cedric-Ververken-Confo.jpg)
Cedric Ververken, Confo Therapeutics CEO
Daiichi Sankyo inks $183M discovery deal with GPCR biotech for CNS target
Belgian biotech Confo Therapeutics has landed $183 million, plus potential royalties, in a drug-discovery deal with Daiichi Sankyo.
Early Thursday, Confo …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.